Livzon Pharmaceutical Group Inc.
Research Livzon Pharmaceutical Group Inc. (1513.HK) on Bullrun: market cap HKD 18.88B, P/E 10.1, dividend yield 11.5%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker1513.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyHKD
- Market capHKD 18.88B
- P/E10.1
- Dividend yield11.5%
- Financial periodQ2 2026
- RevenueCNY 2.13B
- Net incomeCNY 355.29M
- Free cash flowCNY 830.87M
- Gross margin55.1%
Valuation Snapshot
latest market cap is HKD 18.88B; P/E is 10.1; dividend yield is 11.5%.
Peer valuation comparison
Latest P/E is 10.08x versus a Healthcare sector median of 21.8x (53.8% below).
Latest dividend yield is 11.5% versus a Healthcare sector median of 2.4% (379.2% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 18.88B | 10.1 | 7.7% | 1.64 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 1.64 HKD, yield 11.5%.
About Livzon Pharmaceutical Group Inc.
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field;
ETFs that hold Livzon Pharmaceutical Group Inc.
US-listed ETFs
Livzon Pharmaceutical Group Inc. is held by 22 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | <0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| Vanguard FTSE All-World ex-US Index Fund ETF Shares (VEU) | <0.01% | 0.04% |
| Schwab Emerging Markets Equity ETF (SCHE) | <0.01% | 0.06% |
| Vanguard International High Dividend Yield Index Fund ETF Shares (VYMI) | <0.01% | 0.07% |
| State Street SPDR Portfolio Emerging Markets ETF (SPEM) | 0.01% | 0.07% |
| Dimensional Emerging Core Equity Market ETF (DFAE) | <0.01% | 0.29% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Livzon Pharmaceutical Group Inc.'s market cap?
Livzon Pharmaceutical Group Inc.'s market capitalization is HKD 18.88B.
What is Livzon Pharmaceutical Group Inc.'s P/E ratio?
Livzon Pharmaceutical Group Inc.'s price-to-earnings (P/E) ratio is 10.1.
Does Livzon Pharmaceutical Group Inc. pay a dividend?
Livzon Pharmaceutical Group Inc. has a dividend yield of 11.5%.
What does Livzon Pharmaceutical Group Inc. do?
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally.